Cart
sales@molnova.com
ML239
CAS No. 1378872-36-6
ML239( —— )
Catalog No. M17266 CAS No. 1378872-36-6
ML239 is a potent and selective inhibitor of breast cancer stem cells, with an IC50 of 1.16 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 10MG | 29 | In Stock |
|
| 25MG | 57 | In Stock |
|
| 50MG | 109 | In Stock |
|
| 100MG | 186 | In Stock |
|
| 200MG | 272 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameML239
-
NoteResearch use only, not for human use.
-
Brief DescriptionML239 is a potent and selective inhibitor of breast cancer stem cells, with an IC50 of 1.16 μM.
-
DescriptionML239 is a potent and selective inhibitor of breast cancer stem cells, with an IC50 of 1.16 μM.
-
In VitroML239 (Compound 7j) is a potent and selective inhibitor of breast cancer stem cells, with an IC50 of 1.16 μM, with ～24-fold selectivity against the control cell line. ML239 inhibits breast cancer stem-like cells, most likely through activation of fatty acid desaturase 2 (FADS2). ML239 is cytotoxic to NCIH661 cells, and FADS2 knockdown reduces ML239 cytotoxicity, and furthermore, FADS2 inhibitor SC-26196 also reduces ML239 cytotoxicity in cancer cell lines (CCLs).
-
In Vivo——
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetmTOR
-
RecptorOthers
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1378872-36-6
-
Formula Weight346.59
-
Molecular FormulaC13H10Cl3N3O2
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 300 mg/mL 865.55 mM
-
SMILESClc2cc(Cl)cc(Cl)c2OCC(=O)N\N=C\c1cccn1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Germain AR,etal.Identification of a selective small molecule inhibitor of breast cancer stem cells.Bioorg Med Chem Lett. 2012 May 15;22(10):3571-4.
molnova catalog
related products
-
CC-115 hydrochloride
A novel dual inhibitor of mTOR and DNA-PK with IC50 of 21 nM and 13 nM, respectively.
-
BIA
BIA is an inhibitor of the interaction between TMBIM6 and mTORC2, which ultimately blocks AKT activation and cancer progression.
-
XL413 hydrochloride
XL-413 is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity.
